When BCS meets the Frog – Happy Hour Networking Event with JFDI

[bs-text title=”Program” icon=”” title_link=”” heading_color=”” heading_style=”t7-s1″ bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ bs-text-color-scheme=”” custom-css-class=”” custom-id=”” css=””]6:30 PM – 7:00 PM: Registration
7:00 PM – 7:30 PM: Open Mic Session with Happy Hour attendees
7:30 PM – 8:00 PM: Panel Discussion with founders of Genome Editing
8:30 PM – 9:30 PM: Networking reception with light refreshments[/bs-text][bs-text title=”About JFDI” icon=”” title_link=”” heading_color=”” heading_style=”t7-s1″ bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ bs-text-color-scheme=”” custom-css-class=”” custom-id=”” css=””]

JFDI.Asia is a community of people who practice, finance and teach innovation. They believe that innovation need not be a mystery and entrepreneurship should not be painful or lonely. Both can be learned, working with peers and guided by mentors.

Their programs for business startups and professionals lead people to think and act entrepreneurially by helping them to engineer innovative businesses around their ideas. They can do this because innovation is evolving from an art into a science, and they have built a community who share their expertise and experience turning ideas into reality.

Their members are entrepreneurs, investors and innovators in industry. Their partners are grassroots organizations, governments and some of the largest corporations. Their practical work is underpinned by close relationships with the world’s leading academic institutions and independent thinkers.[/bs-text][bs-text title=”Organiser” icon=”” title_link=”” heading_color=”” heading_style=”t7-s1″ bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ bs-text-color-scheme=”” custom-css-class=”” custom-id=”” css=””]

Genome Editing is the ONLY local biotech startup in Singapore selected to compete in the highly competitive OneStart business plan competition in Europe this year. The team intend to provide therapeutic solutions for monogenic or acquired diseases through gene therapy. They developed a lambda-integrase mediated recombination system which enables insertion of large transgenes into a safe harbor site of human genome without need for host DNA repair machinery rendering advantage over currently available gene editing tools such as ZFNs, CRISPR-Cas9,TALENs. This will provide platform for exvivo gene therapy using human reprogrammed stem cells and differentiated progeny.[/bs-text]